Capital Impact Advisors buys $1,911,711 stake in Medivation Inc (MDVN)

Medivation Inc (MDVN) : Capital Impact Advisors scooped up 27,100 additional shares in Medivation Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 13, 2016. The investment management firm now holds a total of 37,360 shares of Medivation Inc which is valued at $1,911,711.Medivation Inc makes up approximately 0.90% of Capital Impact Advisors’s portfolio.

Medivation Inc opened for trading at $52.57 and hit $54.55 on the upside on Monday, eventually ending the session at $53.36, with a gain of 4.28% or 2.19 points. The heightened volatility saw the trading volume jump to 60,15,868 shares. Company has a market cap of $8,764 M.

Other Hedge Funds, Including , Capstone Asset Management Co boosted its stake in MDVN in the latest quarter, The investment management firm added 330 additional shares and now holds a total of 5,904 shares of Medivation Inc which is valued at $302,108. Medivation Inc makes up approx 0.01% of Capstone Asset Management Co’s portfolio.Fjarde Ap-fonden Fourth Swedish National Pension Fund boosted its stake in MDVN in the latest quarter, The investment management firm added 4,334 additional shares and now holds a total of 50,490 shares of Medivation Inc which is valued at $2,583,573. Medivation Inc makes up approx 0.06% of Fjarde Ap-fonden Fourth Swedish National Pension Fund’s portfolio.British Columbia Investment Management Corp reduced its stake in MDVN by selling 9,223 shares or 10.75% in the most recent quarter. The Hedge Fund company now holds 76,591 shares of MDVN which is valued at $3,464,977. Medivation Inc makes up approx 0.03% of British Columbia Investment Management Corp’s portfolio.Creative Planning boosted its stake in MDVN in the latest quarter, The investment management firm added 86 additional shares and now holds a total of 12,537 shares of Medivation Inc which is valued at $567,174.

On the company’s financial health, Medivation Inc reported $0.29 EPS for the quarter, beating the analyst consensus estimate by $ 0.01 according to the earnings call on Feb 25, 2016. Analyst had a consensus of $0.28. The company had revenue of $377.74 million for the quarter, compared to analysts expectations of $372.65 million. The company’s revenue was up 37.5% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.96 EPS.

Many Wall Street Analysts have commented on Medivation Inc. Sun Trust Rbsn Humphrey Initiated Medivation Inc on Apr 6, 2016 to “Buy”, Price Target of the shares are set at $56.Company shares were Reiterated by Credit Suisse on Mar 31, 2016 to “Outperform”, Firm has raised the Price Target to $ 49 from a previous price target of $48 .Medivation Inc was Initiated by Goldman to “Neutral” on Mar 30, 2016.

Medivation Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies to treat serious diseases for which there are limited treatment options. The Company in collaboration with Astellas Pharma Inc. has one commercial product XTANDI (enzalutamide) capsules (XTANDI). XTANDI has received marketing approval in the United States Europe and other countries worldwide for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and in Japan for the treatment of patients with castration-resistant prostate cancer (CRPC). The Company in collaboration with Astellas is also conducting investigational studies of enzalutamide in prostate cancer and in advanced breast cancer. The Company has licensed exclusive worldwide rights to pidilizumab an immune modulatory anti-Programmed Death-1 (PD-1) monoclonal antibody for all potential indications from CureTech Ltd.

Leave a Reply

Medivation Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Medivation Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.